Skip to main content

Table 4 Predicted ADMET properties of the selected compounds

From: In silico evaluation of some 4-(quinolin-2-yl)pyrimidin-2-amine derivatives as potent V600E-BRAF inhibitors with pharmacokinetics ADMET and drug-likeness predictions

SN GI absorption BBB permeant Bioavailability score CYP-substrate/inhibitor
5 Low No 0.55 3A4 1A2 2C19 2C9 2D6
9 Low No 0.55 Yes Yes Yes No Yes
10 Low No 0.55 Yes Yes Yes No Yes
11 Low No 0.55 Yes Yes Yes No Yes
Vem. Low No 0.55 Yes Yes Yes No Yes
  1. GI gastrointestinal system, BBB blood–brain barrier, CYP cytochrome P